T
Teresa Alonso Gordoa
Publications - 23
Citations - 957
Teresa Alonso Gordoa is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 5, co-authored 10 publications receiving 264 citations.
Papers
More filters
Journal ArticleDOI
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert J. Motzer,Boris Alekseev,Sun Young Rha,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Evgeny Kopyltsov,María José Méndez-Vidal,Vadim Kozlov,Anna Alyasova,Sung Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jaime R. Merchan,Eric Winquist,Pablo Maroto,Jeffrey C. Goh,Miso Kim,Howard Gurney,Vijay Patel,Avivit Peer,Giuseppe Procopio,Toshio Takagi,Bohuslav Melichar,Frederic Rolland,Ugo De Giorgi,Shirley Wong,Jens Bedke,Manuela Schmidinger,Corina E. Dutcus,Alan D. Smith,Lea Dutta,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +37 more
TL;DR: In this article, Lenvatinib in combination with pembrolizumab or everolimus has been shown to have activity against advanced renal cell carcinoma (RCC).
Journal ArticleDOI
Pembrolizumab monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (accRCC): Results from cohort A of KEYNOTE-427.
David F. McDermott,Jae-Lyun Lee,Cezary Szczylik,Frede Donskov,Jahangeer Malik,Boris Alekseev,James Larkin,Vsevolod Matveev,Rustem Gafanov,Piotr Tomczak,Scott S. Tykodi,Poul F. Geertsen,Paweł Wiechno,Sang Joon Shin,Frédéric Pouliot,Teresa Alonso Gordoa,Wenting Li,Rodolfo F. Perini,Charles Schloss,Michael B. Atkins +19 more
TL;DR: Programmed death-1 (PD-1) inhibitor–based combination therapy shows clinical benefit in first-line accRCC and limited data on clinical impact of first- line PD-1 inhibitor treatment is limited.
Journal ArticleDOI
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer.
Alfonso Gomez De Liano Lista,Nick van Dijk,Guillermo de Velasco Oria de Rueda,Andrea Necchi,Pernelle Lavaud,Rafael Morales-Barrera,Teresa Alonso Gordoa,Pablo Maroto,Alain Ravaud,Ignacio Duran,Bernadett Szabados,Daniel Castellano,Patrizia Giannatempo,Yohann Loriot,Joan Carles,Georgia Anguera Palacios,Félix Lefort,Daniele Raggi,Marine Gross Goupil,Thomas Powles,Michiel S. van der Heijden +20 more
TL;DR: Patients progressing to frontline ICIs are at risk of early death, excluding them from experiencing potential benefit from chemotherapy, and outcomes after failing immunotherapy are poor, particularly in UC patients who received no prior chemotherapy.
Journal ArticleDOI
DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscle-invasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)-gamma immune signature.
Enrique Grande,Félix Guerrero,Javier Puente,Isabel Galante,Ignacio Duran,M. Domínguez,Teresa Alonso Gordoa,Javier Burgos,Albert Font,Alvaro Pinto,Mario Alvarez-Maestro,Òscar Reig,J. P. Maroto,Xavier Garcia del Muro,Patricia Galván,Juan F. García,Núria Malats,Aleix Prat,Francisco X. Real,Daniel Castellano +19 more
TL;DR: Cisplatin-based neoadjuvant chemotherapy (CT) followed by radical cystectomy (RC) is a standard treatment for MIBC and PD-1/L1 inhibitors as single agent induce pathological complete r...
Journal ArticleDOI
Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study).
Robert J. Motzer,Camillo Porta,Masatoshi Eto,Thomas Powles,Viktor Grünwald,Thomas E. Hutson,Boris Alekseev,Sun Young Rha,Evgeny Kopyltsov,María José Méndez Vidal,Sung-Hoo Hong,Anil Kapoor,Teresa Alonso Gordoa,Jeffrey C. Goh,Jaime R. Merchan,Alan D. Smith,Kalgi Mody,Rodolfo F. Perini,Dongyuan Xing,Toni K. Choueiri +19 more
TL;DR: This data indicates that second-line treatment with LEN + EVE prolonged progression-free survival (PFS) compared with EVE alone in pts with advanced RCC shows preliminary efficacious results.